published meta-analysis   sensitivity analysis   studies

antiviral and associated therapy in COVID 19 all comers - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsLou (FAVIPIRAVIR), 2020 1.12 [0.02; 62.74] NOR-Solidarity (hydroxychloroquine), 2021 3.10 [0.29; 33.20] 2.38[0.31; 18.40]Lou (FAVIPIRAVIR), 2020, NOR-Solidarity (hydroxychloroquine), 202120%131moderatenot evaluable deaths (time to event analysis only)detailed resultsNOR-Solidarity (hydroxychloroquine), 2021 3.10 [0.29; 33.20] 3.10[0.29; 33.20]NOR-Solidarity (hydroxychloroquine), 202110%112NAnot evaluable clinical improvementdetailed resultsLou (FAVIPIRAVIR), 2020 1.25 [0.21; 7.62] 1.25[0.21; 7.62]Lou (FAVIPIRAVIR), 202010%19NAnot evaluable clinical improvement (14-day)detailed resultsLou (FAVIPIRAVIR), 2020 1.25 [0.21; 7.62] 1.25[0.21; 7.62]Lou (FAVIPIRAVIR), 202010%19NAnot evaluable viral clearance detailed resultsLou (FAVIPIRAVIR), 2020 0.18 [0.01; 4.75] 0.18[0.01; 4.75]Lou (FAVIPIRAVIR), 202010%19NAnot evaluable viral clearance by day 14detailed resultsLou (FAVIPIRAVIR), 2020 0.18 [0.01; 4.75] 0.18[0.01; 4.75]Lou (FAVIPIRAVIR), 202010%19NAnot evaluable ICU admissiondetailed resultsLou (FAVIPIRAVIR), 2020 5.43 [0.21; 139.89] 5.43[0.21; 139.89]Lou (FAVIPIRAVIR), 202010%19NAnot evaluable0.010.01.0relative treatment effectwww.metaEvidence.org2024-05-06 23:20 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 94 - treatments: 545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814 - roots T: 290